Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NCX 6560

Drug Profile

NCX 6560

Alternative Names: NCX-6560

Latest Information Update: 08 Oct 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Class Cardiovascular therapies; Heptanoic acids; Pyrroles
  • Mechanism of Action HMG-CoA reductase inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes

Most Recent Events

  • 27 Jul 2012 Discontinued - Phase-I for Acute coronary syndromes in France (PO)
  • 22 Nov 2010 NCX 6560 is available for licensing as of 22 Nov 2010. http://www.nicox.com/update/home_engl.html
  • 18 Nov 2010 Updated efficacy and adverse events data from a phase Ib trial presented at the 83rd Annual Scientific Sessions of the American Heart Association (AHA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top